Should health systems be investing in clinical laboratories at a time when so many are being sold off? It's well known the laboratory industry is facing unprecedented challenges, from revenue pressures under PAMA to the allure of one-time divestment payouts. These dynamics threaten the stability and future of system laboratories, leaving many asking how they can continue to adapt and thrive.
We recently hosted a fireside chat featuring two nationally recognized pathologists to allow them to dive into the critical issues facing the non-profit sector of the laboratory industry. They also provide actionable strategies for safeguarding your lab’s future and unlocking growth opportunities.
Alongside guests representing Clinical Lab 2.0 and The Compass Group, we discuss:
☑️ How shifting healthcare dynamics are reshaping the laboratory industry.
☑️ Proven strategies to elevate your lab’s institutional value beyond commoditized testing.
☑️ Practical business models for aligning with U.S. value-based payment models.
Jump to:
-Speaker intros and overview of Clinical Lab 2.0, Compass Group, and Lighthouse (0:45)
-Reasons health systems outsource labs (14:40)
-Economic factors driving these sales (18:15)
-Leveraging clinical value and lab capacity (25:05)
-How are these outsourcing arrangements working out? (31:30)
-How lab leadership can gain a seat at the table (36:05)
-Insurance considerations and challenges (44:30)
-Can the lab be a profit center? (49:00)
#clinicallaboratory #healthsystems #hospitals #laboratorytesting #laboratorymedicine #pathology